History

CLECELL Co., Ltd. is a bioplatform company that creates a new era in the field of tissue engineering and regenerative medicine through state-of-the-art 3D bioprinting technologies.
Building a business
foundation
2016.12

Foundation of CLECELL, Co. Ltd.

2018.01

Patent Transfer from Harvard Medical School

Participation in KOTRA 2018 KOREA-FRANCE Startup Summit

2018.11

Research support agreement with Brigham and Women's Hospital(Harvard Medical University).

Corporate research lab(institute) establishment

Founding
2021.04

Completion of SNUH-IRB(Institutional Review Board) deliberation- Glioblastoma (GBM) 3D bioprinting cancer organoid model clinical research.

2021.07

E. Technical transfer (TT) agreement with TPC Mechatronics PLC for CLECELL’s product (research model) U-FAB ACTIVO.

2019.05

Formation of Boston Bioprinting Consortium (BBC) consisting of members of doctors and professors from the Boston area of the United States

Certification as a Venture Company

2020.03

U-FAB (3D bioprinter) development

2020.06

3D artificial skin (U-skin) production protocol establishment

2020.08

3D Atopy Skin Model Development for Atopy Disease Treatment and Atopy Therapeutic Agent Screening Kit through Joint Research Agreement with Korea University Technology Holding Company

2020.09

Provision of U FAB 3D bioprinter to Harvard Medical School for joint research

2020.12

3D bioprinting cancer organoid model development (brain cancer, breast cancer, skin cancer)

Business model
expansion